Armour Thyroid FDA Approval History

Pre-1938: A Drug That Predates the FDA Itself

Armour Thyroid entered clinical use in the 1890s, decades before Congress established the regulatory architecture that governs pharmaceutical products today. Physicians began prescribing desiccated animal thyroid gland for myxedema (severe hypothyroidism) in 1891, and Armour & Company, a Chicago meatpacking firm, commercialized the preparation shortly after by extracting and tableting porcine thyroid tissue as a pharmaceutical byproduct.

The Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938 required that new drugs demonstrate safety before marketing. Drugs already on the market before that date were not subject to this requirement. Armour Thyroid fell squarely into this pre-1938 category 1. It continued to be sold without an approved NDA, a status the FDA later characterized as "marketed unapproved."

This grandfather clause created a durable loophole. For most of the twentieth century, Armour Thyroid required no formal FDA approval to remain on pharmacy shelves. No key clinical trial data, no bioequivalence study, and no FDA review of safety and efficacy were demanded of the manufacturer. The product simply persisted.

The 1962 Kefauver-Harris Amendment and the DESI Review

The thalidomide crisis of the early 1960s prompted Congress to pass the Kefauver-Harris Amendment in 1962, which added an efficacy requirement for all drugs approved between 1938 and 1962. The FDA contracted the National Academy of Sciences to evaluate these drugs under the Drug Efficacy Study Implementation (DESI) program 2.

DESI panels reviewed thyroid hormones as a class. The conclusion: thyroid hormone preparations were "effective" for treating hypothyroidism and certain forms of thyroid cancer. This finding applied broadly to levothyroxine, liothyronine, liotrix, and desiccated thyroid 2. The DESI process, however, did not grant formal NDA approval. Products classified as "effective" still needed to submit NDAs or Abbreviated New Drug Applications (ANDAs) to achieve full regulatory standing.

For synthetic levothyroxine (Synthroid, Levoxyl, and others), this unresolved status persisted for decades. For Armour Thyroid and other NDT products, it persists to this day.

The 1997 FDA Enforcement Action on Levothyroxine

The FDA's most consequential regulatory intervention in the thyroid drug space came on August 14, 1997, when the agency published a Federal Register notice declaring that orally administered levothyroxine sodium products were "new drugs" and required approved NDAs 3. The agency cited documented quality problems: 150 recalls of levothyroxine products between 1991 and 1997 due to potency and stability failures.

The 1997 notice gave manufacturers three years to submit NDAs. Synthroid (then manufactured by Knoll Pharmaceutical) ultimately received NDA approval in 2002. Levoxyl followed in 2001. Unithroid received its NDA in 2000. That enforcement action reshaped the synthetic levothyroxine market.

Armour Thyroid was not directly targeted by this specific enforcement action, which focused on levothyroxine sodium. The FDA's Compliance Policy Guide on marketed unapproved drugs acknowledges that many pre-1938 drugs, including certain NDT products, remain on the market without approved NDAs 1. The agency has not, as of 2026, initiated formal enforcement requiring NDT manufacturers to submit NDAs.

Why Armour Thyroid Still Lacks an NDA

Three factors explain the continued absence of a formal NDA for Armour Thyroid.

Regulatory inertia and prioritization. The FDA's 2006 Compliance Policy Guide for marketed unapproved drugs established a risk-based enforcement framework. The agency prioritized action against unapproved drugs that posed safety risks, made fraudulent claims, or lacked evidence of effectiveness 1. Armour Thyroid, with over a century of clinical use and a DESI finding of effectiveness, ranked low on the enforcement priority list.

USP monograph compliance. Armour Thyroid is manufactured to meet the United States Pharmacopeia (USP) monograph for thyroid tablets, which specifies content requirements for T4 and T3 4. Each 60 mg (1 grain) tablet must contain approximately 38 micrograms of levothyroxine (T4) and 9 micrograms of liothyronine (T3). This pharmacopeial standard provides a quality baseline even without NDA-level oversight.

Commercial succession. Armour Thyroid has changed hands multiple times. Armour & Company's pharmaceutical division was eventually acquired by Revlon's USV Pharmaceutical division, then by Forest Laboratories, then by Allergan, and most recently by AbbVie. Each acquisition complicated the regulatory calculus, as new owners inherited a product with no NDA obligation and little commercial incentive to voluntarily pursue one.

What the Armour Thyroid Label Actually States

The current prescribing information for Armour Thyroid describes the product as "the preparation of choice for thyroid hormone replacement" in certain older medical literature, while acknowledging that the American Thyroid Association (ATA) 2014 guidelines recommend levothyroxine monotherapy as the standard treatment for hypothyroidism 5.

The label lists approved indications as hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis) and as a pituitary TSH suppressant in the treatment and prevention of certain thyroid cancers and nodular disease. It carries the standard thyroid hormone boxed warning: thyroid hormones should not be used for the treatment of obesity, and doses within the range of daily hormonal requirements are ineffective for weight reduction in euthyroid patients.

Dr. Victor Bernet, then-president of the ATA, stated in 2013 that "desiccated thyroid extracts are not recommended as a routine replacement for levothyroxine due to concerns about variable hormone content and the lack of long-term outcome data" 5. This position reflects the broader endocrine community's preference for synthetic T4 monotherapy, a preference rooted more in standardization concerns than in evidence of harm from NDT.

The Hoang 2013 Trial: Key Evidence for Desiccated Thyroid

The most frequently cited randomized trial comparing desiccated thyroid extract (DTE) to levothyroxine was published by Hoang et al. in the Journal of Clinical Endocrinology & Metabolism in 2013. This crossover trial enrolled 70 patients with hypothyroidism who received either DTE or levothyroxine for 16 weeks each 4.

Results showed no difference in the primary outcome of neurocognitive function. Patients lost a mean of approximately 3 pounds more on DTE than on levothyroxine (P = 0.02). Nearly 49% of participants preferred DTE, while 19% preferred levothyroxine (P = 0.001) 4. Free T3 levels were higher on DTE, and serum TSH was slightly more suppressed during the DTE phase.

Hoang et al. wrote: "DTE therapy did not result in a significant improvement in quality of life; however, DTE caused modest weight loss and nearly half the study subjects expressed preference for DTE over L-T4" 4. The study's small sample size and 16-week duration limited its ability to detect differences in hard clinical endpoints, but it remains the strongest RCT evidence available for NDT products as of 2026.

A 2021 survey published in Thyroid found that approximately 5% of U.S. hypothyroid patients use desiccated thyroid products, and these patients report higher satisfaction scores than those on levothyroxine monotherapy 6.

Safety Considerations Specific to the Regulatory Gap

The absence of an NDA means Armour Thyroid has not undergone the same post-approval pharmacovigilance requirements as NDA-approved drugs. No Risk Evaluation and Mitigation Strategy (REMS) exists. No FDA-mandated post-marketing studies have been required.

This creates several concrete gaps. Batch-to-batch potency data is monitored through USP standards and manufacturer quality control, not through FDA-audited bioequivalence studies 7. Adverse event reporting still occurs through the FDA's MedWatch system, but without the structured post-marketing commitments that accompany NDA-approved products.

The fixed T4:T3 ratio in NDT is approximately 4.2:1, compared to the human thyroid's secretion ratio of roughly 14:1. This means patients taking Armour Thyroid receive a supraphysiologic proportion of T3 relative to T4 4. The clinical significance of this ratio difference is debated, but it can produce transiently elevated T3 peaks after dosing.

The 2014 ATA guidelines note that "the recommendation to use levothyroxine alone is based in part on the lack of randomized outcome data with combination therapy or desiccated thyroid lasting longer than one year" 5. The absence of long-duration trials is itself partly a consequence of the regulatory framework: without NDA requirements, no regulatory mechanism compels the manufacturer to fund them.

Comparing the Regulatory Status of Thyroid Products

Levothyroxine sodium products (Synthroid, Levoxyl, Tirosint, Unithroid) all hold approved NDAs. The FDA required these after the 1997 Federal Register notice 3. Liothyronine sodium (Cytomel) also holds an approved NDA.

Armour Thyroid, Nature-Throid, and WP Thyroid (all desiccated thyroid products) do not hold approved NDAs. Nature-Throid and WP Thyroid, manufactured by RLC Labs, experienced severe supply disruptions in 2020 and 2021 and have had intermittent availability since. NP Thyroid, manufactured by Acella Pharmaceuticals, also lacks an approved NDA and was subject to a voluntary recall in 2020 due to superpotent tablets containing approximately 30% more T3 than the labeled amount 8.

That NP Thyroid recall illustrates the risk profile of the regulatory gap. An NDA-approved drug would have been subject to pre-approval bioequivalence testing and more rigorous lot-release testing requirements. The recalled NP Thyroid lots reached patients before the potency deviation was detected.

Dr. Elizabeth Pearce, a thyroid researcher at Boston University, observed in a 2020 editorial that "the lack of NDA approval for desiccated thyroid products means these medications are not subject to the same manufacturing oversight as FDA-approved alternatives" 9.

Ongoing Regulatory Outlook

The FDA has shown no public indication that it plans to require NDA submissions from NDT manufacturers in the near term. The agency's 2023 update to its marketed unapproved drug compliance guidance did not single out thyroid products for new enforcement 1.

Patient advocacy groups, including the American Thyroid Association's patient education arm, continue to call for better regulatory oversight of all thyroid products, with and without NDAs 5. Some clinicians argue that the appropriate response is not to remove NDT from the market but to require the same NDA-level evidence that synthetic products now provide.

For prescribers and patients currently using Armour Thyroid, the practical implications of its unapproved status are: (1) formulary coverage may be inconsistent because insurers sometimes decline to cover non-NDA drugs; (2) generic substitution laws, which apply to NDA/ANDA-approved products, do not formally apply; and (3) any manufacturing disruption lacks the FDA recall authority framework that applies to NDA-approved products.

Monitoring thyroid function every 6 to 8 weeks after initiating or changing Armour Thyroid dosing remains the standard clinical recommendation, consistent with the ATA's guidance for all thyroid hormone preparations 5.